ClinicalTrials.gg
RecruitingNCT06688331PreTregUpdated Jul 17, 2026

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

A Phase 2 interventional study of ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) and Anti-CD20 (rituximab) in Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I and Diabetes Mellitus, Type 1, sponsored by PolTREG S.A.. Recruiting at 9 sites in Poland. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by PolTREG S.A. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 92 studies in Diabetes Mellitus, Type 1 with a site in Poland — 13 open to participants now, 18 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Poland.

Planned enrollment
48th of 74
150 · median 315
Started
2025
with 8 others
Phase 2
9 of 92
4 open now
Primary completion
2032-12
later than 17 of 17 live
Registered
80th of 92
by date

Among the 92 studies in Diabetes Mellitus, Type 1 with a site in Poland, this one is the 48th largest by planned enrollment of the 74 interventional ones that give a count, is one of 9 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 17 of the 17 other live ones, and was the 80th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

13 of the 92 studies in Diabetes Mellitus, Type 1 with a site in Poland are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Diabetes Mellitus, Type 1 with a site in Poland, or all of them as a file.
02

Study summary

The main purpose of the study is to check:

  • Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or delay type 1 diabetes?
  • Is therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or a preparation of antiCD20 antibodies (rituximab) safe for children with pre-diabetes, and what side effects may be associated with it? The study will include patients at high risk for type 1 diabetes whose laboratory tests have confirmed preserved normal/high insulin production. First (part 1 of the study), tests will be performed to determine the risk of the disease (determination of autoantibodies that characterize the autoimmune background).

In order to confirm the effectiveness of the therapy, not all patients will receive the study treatment. The study will be a so-called blinded randomized trial. This means that in this trial, all participants will undergo the same study procedures, but the participant will be randomly assigned to one of four (4) groups that will receive different treatment regimens before entering the study.

The participant will be randomly assigned to one of four groups:

  • Group I will receive a preparation of regulatory cells (Tregs lymphocytes) along with a preparation of antiCD20 antibodies,
  • Group II will receive a preparation of regulatory cells (Tregs lymphocytes) together with an inert substance (placebo)
  • Group III will receive a preparation of antiCD20 antibodies along with a sham treatment (inert substance)
  • Group IV will receive an agent containing an inert substance and sham treatment.

Approximately 150 patients aged 3-18 who are at risk of developing type 1 diabetes will be enrolled in the study, which will last up to 96 months. Each enrolled participant will remain in the study for up to five years.

Read the detailed description

Participants: screening of approximately 2500 high-risk subjects will be conducted until no less than 150 participants with confirmed stage 1 (preclinical) type 1 diabetes mellitus are randomized; randomization 2:1:1:2; 50 participants treated with Tregs and anti-CD20 antibody; 25 participants treated with Tregs; 25 participants treated with anti-CD20 antibody; control: 50 participants receiving placebo and sham Tregs.

Inclusion of participants: up to 36 months. Trial intervention: Total duration of the trial intervention for each participant will be approximately 3 Months. After completion of the trial intervention, participants will be monitored at the sites for the onset of type 1 diabetes mellitus for a maximum of five years counting from the first dose of Tregs.

Follow-up time: post-treatment observation of all participants to 57 months (day "0" is the day of administration of the first dose of Treg/sham preparation).

Trial time: 96 months. Trial type: Prospective randomized (phase 2), placebo-controlled, parallel group, blinded trial.

Blinding: The following roles indicated below will not be made aware of the treatment group assignment during the trial:

  • participant
  • legal representatives
  • site staff excluding pharmacists (applies to anti-CD20only)
03

Conditions studied

  • Presymptomatic Diabetes Type 1 (Stage 1)
  • Diabetes Mellitus, Type I
  • Diabetes Mellitus, Type 1

Keywords

  • PreTreg
  • Tregs
  • Prediabetes
  • presymptomatic
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 3-18
  2. 5 ≤ ≤ 95 percentile (acc. to OLAF, or WWF in the case of children under six years old) with a lower weight threshold of 20 kg
  3. Venous plasma glucose levels \< 100mg% at fasting (70 to 100 mg/dl) and normal glucose tolerance test (at 120 minutes glycaemia \<140 mg/dl) (acc. to PTD)
  4. Insulin independence
  5. C-peptide levels ≥ 1.0 ng/ml (central laboratory limit of normal) in fasting and post-stimulation tests increase ≥ 100%
  6. Participant has not yet been diagnosed with stage 2 or 3 type 1 diabetes mellitus (no history of dysglycemia, no history of clinical symptoms of type 1 diabetes mellitus)
  7. level (%) \<5,7% (acc. to ADA)
  8. Positive autoantibody titres (ICA, IAA, GAD, IA-2/ICA512, ZnT8) - low titers of two or more antibodies (2 times the normal* or higher); if high titer of one of the antibodies (≥ 4 times the norm, not applicable to ICA) re-screening allowed (the participant can be included in the trial only after confirming two or more antibodies)
  9. Ability to give by the child's legal representatives (and the child himself or herself if he or she is over the age of 13 at the time of the trial [according to local law])
  10. Ability of the child's legal representatives to manage diabetes, defined as blood glucose levels control at least three times a day and the ability to dose insulin correctly.
  11. Venous access to guarantee blood donation

    * Standard defined depending on the method used

Exclusion criteria

Exclusion Criteria:

  1. Refusal to participate in the trial or lack of a signed form
  2. Suspicion or diagnosis for a type of diabetes other than type 1 diabetes mellitus
  3. Age under 3 or above 18
  4. IgA deficiency or history of other diagnosed immunodeficiency (max. 7 infections/year allowed, and the prognosis should indicate that the patient will remain in the study throughout its duration)
  5. C-peptide levels \< 1.0 ng/ml fasting and in post-stimulation tests increase \< 100%
  6. Glucose levels in venous blood ≥ 100mg% fasting
  7. Glucose levels in venous blood after 1 and 2 hours in OGTT ≥ 200mg%
  8. level (HbA1c) in venous blood ≥ 5,7%
  9. \< 5th percentile or > 95th percentile for age, or body weight \< 20 kg
  10. History of to anti-CD20 or other components of the preparation
  11. History of hypersensitivity to penicillin and/or streptomycin
  12. Past or active infection with , , , HTLV I/II, mycobacterium tuberculosis, syphilis. Laboratory evidence of infection without the need for clinical signs and symptoms is sufficient for diagnosis.
  13. Active infection with the EBV or CMV virus (positive IgM)
  14. Any fungal, parasitic, viral, or bacterial infection
  15. History of past or active cancer
  16. Anemia, lymphopenia, neutropenia, or thrombocytopenia defined as a blood cell count below the lower limit of normal for age found within the last 6 weeks prior to trial inclusion
  17. Elevated thrombotic activity/history of thrombosis episode
  18. Any disease prior to inclusion in the trial currently requiring medication for more than 3 months in history
  19. Diagnosed disease other than type 1 diabetes mellitus, including a history of Hashimoto's disease and coeliac disease
  20. Taking anti-diabetic medication (including insulin) in the last 4 weeks prior to trial inclusion
  21. History of retinopathy
  22. History of hypertension
  23. Current or history of albuminuria
  24. For women in /menstruating women: pregnancy (from medical interview) or unwillingness to exercise sexual restraint or use effective forms of for the duration of the trial and up to 4 months after completion, if applicable.

    The following contraceptive methods are acceptable: bilateral fallopian tube closure, sterilization in men, appropriate use of hormonal contraception that inhibits ovulation, hormone-releasing IUDs, and copper IUDs, male or female condoms with spermicide; and cap, uterine disc, or sponge with spermicide.

  25. Breastfeeding
  26. For males over 15 years of age: expressed intention to have offspring or donate sperm during the trial or within 4 months after the end of the trial, if applicable
  27. Excessive anxiety of the participant or his/her legal representatives regarding the procedures used in the trial
  28. Any medical problem that, in the opinion of the investigator, may adversely affect the participant's health if included in the trial
  29. Legal representatives and/or children over the age of 15 with an identified alcohol and/or psychoactive substance addiction
  30. History of disease of unknown etiology
  31. History of Creutzfeldt-Jacob disease
  32. History of progressive dementia or degenerative neurological disease, including of unknown origin
  33. History of taking hormones derived from the human pituitary gland (e.g., growth hormone)
  34. Treatment with
  35. History of corneal, scleral, and dural transplant or undocumented neurosurgery
  36. History of occurrence of risk factors related to the participant's travel, where there is a possibility of exposure to regional infectious diseases
  37. Physical signs that indicate the risk of an infectious disease
  38. History of xenogeneic transplant
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    TregsCD20

    Infusion of Treg preparation at "day 0" + 4 doses of antiCD20 antibody; second infusion of Treg preparation at time "+90 (+30) days" Interventions: ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) + Anti-CD20 (rituximab)

    Biological: ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) · Biological: Anti-CD20 (rituximab)

  • Experimental
    Tregs only

    Infusion of Treg preparation at "day 0" + 4 doses of placebo; second infusion of Treg preparation at time "+90 (+30) days"

    Biological: ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) · Other: Placebo

  • Experimental
    CD20 only

    Infusion of Treg sham at "day 0" + 4 doses of antiCD20 antibody; second infusion of Treg sham at time "+90 (+30) days"

    Biological: Anti-CD20 (rituximab) · Other: Treg sham

  • Placebo comparator
    Control group

    Infusion of Treg sham at "day 0" + 4 doses of placebo; second infusion of Treg sham at time "+90 (+30) days"

    Other: Placebo · Other: Treg sham

Interventions

  • Biologicalex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs)

    regulatory T cells with the phenotype CD3(+)CD4(+)CD25(high)CD127(-)doublet(-)lin(-)

    Also known as: Tregs, regulatory T cells

  • BiologicalRituximabStudies of RituximabRituximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    rituximab

    Also known as: Mabthera

  • OtherPlacebo

    intrevenous 0,9% NaCl

  • OtherTreg sham

    intrevenous 0,9% NaCl

06

What researchers measure

Primary outcomes

  1. % of participants in each group who are still in stage 1 type 1 diabetes mellitus, i.e., presence of autoantibodies and normoglycemia or in stage 2 type 1 diabetes mellitus, i.e., presence of autoantibodies, dysglycemia or stage 3 at the end of the trial

    To assess the safety and efficacy of the treatment used in the separate groups of participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/Tregs sham)

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  2. Number of adverse events reported 1 year, 2 years after the first dose of Tregs and at the end of the trial comparing to control arms

    To assess the safety and efficacy of the treatment used in the separate groups of participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/Tregs sham)

    Time frame: From enrollment to the end of participation in the trial at month 60 (day "0" is the day of administration of the first dose of Treg preparation)

Secondary outcomes

  1. Pace of diabetes development. Total number of days from the date of diagnosis of stage 2 to the date of onset of full-blown type 1 diabetes mellitus (stage 3 of type 1 diabetes mellitus) in each group (normalized to the number of person/days in each grou

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  2. Number of days from day 0 to the day of first dysglycemia (stage 2 of type 1 diabetes mellitus) in each group

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  3. Cumulative diabetes incidence [only the progression to stage 3 considered as diabetes incidence]

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  4. C-peptide levels [fasting/post MMTT stimulation (AUC)] 1 year, 2 years after the first dose of Tregs and then annually until the end of the trial comparing to control arms

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  5. Daily average dose of insulin per kg body weight (DDI) 1 year, 2 years after the first dose of Tregs, and annually thereafter until the end of the trial in each arm of the trial

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  6. Number of participants per arm in remission 1 year, 2 years after the first dose of Tregs, and annually thereafter until the end of the trial, [remission defined as daily insulin dose is less than 0.5U/kg/day with an HbA1c level less than 6.5%]

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

  7. Assessment of the incidence and severity of adverse events associated with the administration of Treg preparation or anti-CD20 antibody, primarily the effects of immunosuppression: incidence of infections of any etiology and de novo tumors detected

    Additional measures to assess the safety and efficacy of the treatment used in the separate groups of pediatric participants treated with combined treatment with Treg preparation and rituximab antibody or Treg preparation or rituximab antibody or the control (placebo/ Tregs sham) in preserving β-cell function

    Time frame: From day "0" (the day of administration of the first dose of Treg preparation) to the end of participation in the trial at month 60

07

Study locations

8 of 9 sites recruiting
  • Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku
    Bialystok, 15-269, Poland
    Recruiting
    • Artur Bossowski, prof · Principal investigator
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-211, Poland
    Recruiting
    • Matylda Hennig, Dr · Principal investigator
  • Gornoslaskie Centrum Zdrowia Dziecka Im. Sw. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 Slaskiego Uniwersytetu Medycznego W Katowicach
    Katowice, 40-752, Poland
    Not yet recruiting
    • Przemyslawa Jarosz-Chobot, prof · Principal investigator
  • Uniwersytet Medyczny W Lodzi
    Lodz, 90-419, Poland
    Recruiting
    • Agnieszka Szadkowska, prof · Principal investigator
  • Uniwersytecki Szpital Dzieciecy w Lublinie
    Lublin, 20-093, Poland
    Recruiting
    • Iwona Ben-Skowronek, prof · Principal investigator
  • Uniwersytecki Szpital Kliniczny w Opolu
    Opole, 45-401, Poland
    Recruiting
    • Agata Chobot, prof · Principal investigator
  • Centrum Medyczne Medyk Sp. z o.o. S.K.
    Rzeszów, 35-326, Poland
    Recruiting
    • Artur Mazur, prof · Principal investigator
  • Pomorski Uniwersytet Medyczny w Szczecinie
    Szczecin, 71-252, Poland
    Recruiting
  • Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
    Wroclaw, 50-556, Poland
    Recruiting
    • Agnieszka Zubkiewicz-Kucharska, dr · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2032, 93 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 93 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2024
First posted
Nov 14, 2024
StartActual
Mar 12, 2025
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06688331
Lead sponsor
PolTREG S.A.
Collaborators
Invicta Sp. z o.o., Medical Research Agency, Poland, Clinmark Clinical Research
Responsible party
Sponsor
First posted
Nov 14, 2024
Start date
Mar 12, 2025
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jul 17, 2026

Study contacts

Marta Druch, Clinical Trial Director
Contact
m.druch@poltreg.com
+48731471845
Katarzyna Karpinska, Sr Clinical Trial Specialist
Contact
k.karpinska@poltreg.com
+48537504486
Piotr Trzonkowski, Prof
study director · PolTREG S.A.
Artur Bossowski, Prof
principal investigator · Uniwersytecki Dzieciecy Szpital Kliniczny Im. L. Zamenhofa W Bialymstoku
Wojciech Mlynarski, Prof
study chair · Uniwersytet Medyczny W Lodzi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion